Pharmaco 2000 Limited - Accounts to registrar (filleted) - small 23.1.5

Pharmaco 2000 Limited - Accounts to registrar (filleted) - small 23.1.5


IRIS Accounts Production v23.1.5.20 02981896 Board of Directors 1.4.22 31.3.23 31.3.23 false true false false true false Fair value model Preference A Shares 0.25000 Ordinary Class B 0.25000 Ordinary Class C 0.25000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure029818962022-03-31029818962023-03-31029818962022-04-012023-03-31029818962021-03-31029818962021-04-012022-03-31029818962022-03-3102981896ns16:EnglandWales2022-04-012023-03-3102981896ns15:PoundSterling2022-04-012023-03-3102981896ns11:Director12022-04-012023-03-3102981896ns11:PrivateLimitedCompanyLtd2022-04-012023-03-3102981896ns11:SmallEntities2022-04-012023-03-3102981896ns11:AuditExempt-NoAccountantsReport2022-04-012023-03-3102981896ns11:SmallCompaniesRegimeForDirectorsReport2022-04-012023-03-3102981896ns11:SmallCompaniesRegimeForAccounts2022-04-012023-03-3102981896ns11:FullAccounts2022-04-012023-03-3102981896ns11:OrdinaryShareClass12022-04-012023-03-3102981896ns11:OrdinaryShareClass22022-04-012023-03-3102981896ns11:OrdinaryShareClass32022-04-012023-03-3102981896ns11:Director22022-04-012023-03-3102981896ns11:Director32022-04-012023-03-3102981896ns11:CompanySecretary12022-04-012023-03-3102981896ns11:RegisteredOffice2022-04-012023-03-3102981896ns6:CurrentFinancialInstruments2023-03-3102981896ns6:CurrentFinancialInstruments2022-03-3102981896ns6:ShareCapital2023-03-3102981896ns6:ShareCapital2022-03-3102981896ns6:SharePremium2023-03-3102981896ns6:SharePremium2022-03-3102981896ns6:FurtherSpecificReserve1ComponentTotalEquity2023-03-3102981896ns6:FurtherSpecificReserve1ComponentTotalEquity2022-03-3102981896ns6:RetainedEarningsAccumulatedLosses2023-03-3102981896ns6:RetainedEarningsAccumulatedLosses2022-03-3102981896ns6:PlantMachinery2022-04-012023-03-3102981896ns6:ShortLeaseholdAssetsns6:LandBuildings2022-03-3102981896ns6:PlantMachinery2022-03-3102981896ns6:ShortLeaseholdAssetsns6:LandBuildings2022-04-012023-03-3102981896ns6:ShortLeaseholdAssetsns6:LandBuildings2023-03-3102981896ns6:PlantMachinery2023-03-3102981896ns6:ShortLeaseholdAssetsns6:LandBuildings2022-03-3102981896ns6:PlantMachinery2022-03-3102981896ns6:CostValuation2022-03-3102981896ns6:DisposalsRepaymentsInvestments2023-03-3102981896ns6:CostValuation2023-03-3102981896ns6:WithinOneYearns6:CurrentFinancialInstruments2023-03-3102981896ns6:WithinOneYearns6:CurrentFinancialInstruments2022-03-3102981896ns6:DeferredTaxation2022-03-3102981896ns6:DeferredTaxation2022-04-012023-03-3102981896ns6:DeferredTaxation2023-03-3102981896ns11:OrdinaryShareClass12023-03-3102981896ns11:OrdinaryShareClass22023-03-3102981896ns11:OrdinaryShareClass32023-03-3102981896ns6:RetainedEarningsAccumulatedLosses2022-03-3102981896ns6:SharePremium2022-03-3102981896ns6:FurtherSpecificReserve1ComponentTotalEquity2022-03-3102981896ns6:RetainedEarningsAccumulatedLosses2022-04-012023-03-31
REGISTERED NUMBER: 02981896 (England and Wales)



















Unaudited Financial Statements

for the Year Ended 31 March 2023

for

PHARMACO 2000 LIMITED

PHARMACO 2000 LIMITED (REGISTERED NUMBER: 02981896)






Contents of the Financial Statements
for the Year Ended 31 March 2023




Page

Company Information 1

Statement of Financial Position 2

Notes to the Financial Statements 4


PHARMACO 2000 LIMITED

Company Information
for the Year Ended 31 March 2023







DIRECTORS: Kamruddin Fidahusein Khaki
Mushtaq Jafferali Ismail
Mustakali Pyarali Hassanali Kurji



SECRETARY: Mustakali Pyarali Hassanali Kurji



REGISTERED OFFICE: Unit 4
Boultbee Business Units
Nechells Place
Birmingham
West Midlands
B7 5AR



REGISTERED NUMBER: 02981896 (England and Wales)



ACCOUNTANTS: Brindleys Limited
2 Wheeleys Road
Edgbaston
Birmingham
West Midlands
B15 2LD



BANKERS: Lloyds TSB Bank Plc
538 Stratford Road
Sparkhill
Birmingham
West Midlands
B11 4BD

PHARMACO 2000 LIMITED (REGISTERED NUMBER: 02981896)

Statement of Financial Position
31 March 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 15,229 18,602
Investments 5 111 112
Investment property 6 565,000 565,000
580,340 583,714

CURRENT ASSETS
Debtors 7 480,627 554,757
Cash at bank and in hand 2,464,464 1,645,382
2,945,091 2,200,139
CREDITORS
Amounts falling due within one year 8 346,328 293,300
NET CURRENT ASSETS 2,598,763 1,906,839
TOTAL ASSETS LESS CURRENT
LIABILITIES

3,179,103

2,490,553

CAPITAL AND RESERVES
Called up share capital 10 13,012 13,012
Share premium 11 23,308 23,308
Capital redemption reserve 11 2 2
Retained earnings 11 3,142,781 2,454,231
SHAREHOLDERS' FUNDS 3,179,103 2,490,553

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

PHARMACO 2000 LIMITED (REGISTERED NUMBER: 02981896)

Statement of Financial Position - continued
31 March 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 8 August 2023 and were signed on its behalf by:





Mushtaq Jafferali Ismail - Director


PHARMACO 2000 LIMITED (REGISTERED NUMBER: 02981896)

Notes to the Financial Statements
for the Year Ended 31 March 2023

1. STATUTORY INFORMATION

Pharmaco 2000 Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 25% on reducing balance

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Investment property
Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

PHARMACO 2000 LIMITED (REGISTERED NUMBER: 02981896)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2023

2. ACCOUNTING POLICIES - continued

Holiday pay
Holiday pay is recognised as an expense in the period in which the service is received.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 4 (2022 - 4 ) .

4. TANGIBLE FIXED ASSETS
Short Plant and
leasehold machinery Totals
£    £    £   
COST
At 1 April 2022 36,950 88,432 125,382
Additions - 882 882
At 31 March 2023 36,950 89,314 126,264
DEPRECIATION
At 1 April 2022 24,634 82,146 106,780
Charge for year 2,463 1,792 4,255
At 31 March 2023 27,097 83,938 111,035
NET BOOK VALUE
At 31 March 2023 9,853 5,376 15,229
At 31 March 2022 12,316 6,286 18,602

5. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 April 2022 112
Disposals (1 )
At 31 March 2023 111
NET BOOK VALUE
At 31 March 2023 111
At 31 March 2022 112

PHARMACO 2000 LIMITED (REGISTERED NUMBER: 02981896)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2023

6. INVESTMENT PROPERTY
Total
£   
FAIR VALUE
At 1 April 2022
and 31 March 2023 565,000
NET BOOK VALUE
At 31 March 2023 565,000
At 31 March 2022 565,000

Fair value at 31 March 2023 is represented by:
£   
Valuation in 2018 55,501
Valuation in 2020 66,229
Valuation in 2021 (45,000 )
Valuation in 2022 35,000
Cost 453,270
565,000

If investment properties had not been revalued they would have been included at the following historical cost:

2023 2022
£    £   
Cost 453,270 453,270

Investment properties were valued on a fair value basis on 31 March 2022 by the directors .

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade debtors 259,762 253,957
Amounts owed by group undertakings 66,451 276,451
Other debtors 138,407 12,652
Deferred tax asset 16,007 11,697
480,627 554,757

PHARMACO 2000 LIMITED (REGISTERED NUMBER: 02981896)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2023

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade creditors 23,394 29,303
Corporation Tax 95,822 70,851
VAT 92,960 84,436
Other creditors 15 3,401
Accrued expenses 134,137 105,309
346,328 293,300

9. DEFERRED TAX
£   
Balance at 1 April 2022 (11,697 )
Provided during year (4,310 )
Balance at 31 March 2023 (16,007 )

10. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2023 2022
value: £    £   
50,875 Preference A Shares £0.25 12,719 12,719
36 Ordinary Class B £0.25 9 9
1,134 Ordinary Class C £0.25 284 284
13,012 13,012

.

11. RESERVES
Capital
Retained Share redemption
earnings premium reserve Totals
£    £    £    £   

At 1 April 2022 2,454,231 23,308 2 2,477,541
Profit for the year 703,587 703,587
Dividends (15,037 ) (15,037 )
At 31 March 2023 3,142,781 23,308 2 3,166,091